Mirati Therapeutics specializes in developing cancer treatments targeting genetic and immunological causes, with Krazati being their first FDA-approved product. Krazati is used to treat adult patients ...
The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. The Boston biotech has decided to discontinue a phase 1/2 trial in advanced KRAS G12C-mutated ...
REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, ...
The KRAS G12C gene mutation in non-small cell lung cancer has been deemed “undruggable,” but recent effective therapies have successfully targeted this mutation, leading to shrinking of tumors and ...
D3S-001 received FDA breakthrough therapy and orphan drug designations for KRAS G12C-mutated NSCLC and CRC, expediting its development for serious and rare conditions. KRAS G12C mutations are ...
JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results